The UAB Alzheimer's Disease Center participates in several national collaborative research programs investigating AD and potential new therapies.  These include:

ACTC LogoAlzheimer's Clinical Trial Consortium (ACTC). The ACTC provides a clinical trials infrastructure designed to accelerate and expand studies for therapies in Alzheimer's disease and related dementias. ACTC's mission is to provide an optimal infrastructure, utilizing centralized resources and shared expertise, to accelerate the development of effective interventions for Alzheimer’s disease and related disorders. Dr. Geldmacher serves as UAB's representative on the Steering Committee.

ADNIAlzheimer's Disease Neuroimaging Initative (ADNI). Since 2005, the longitudinal Alzheimer’s Disease Neuroimaging Initiative (ADNI) has been validating the use of biomarkers including blood tests, tests of cerebrospinal fluid, and MRI/ PET imaging for Alzheimer’s disease (AD) clinical trials and diagnosis. UAB has participated in each phase of this study, including ADNI-1, ADNI-GO, ADNI-2, and now ADNI-3.

Alzheimer's Disease Genetics Consortium (ADGC). The ADGC is an NIH-funded ADGC logocollaboration between Alzheimer's Disease Centers across the U.S. to identify genetic variants that contribute to AD risk.

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL). The ARTFL consortium is an integrated group of academic medical centers partnered with patient support organizations and dedicated to ARTFL logoconducting clinical research in sporadic and familial frontotemporal lobar degeneration (FTLD) syndromes. ARTFL is funded by the National Institutes of Health and is part of the Rare Diseases Clinical Research Network. Dr. Roberson is the site PI at UAB.

ADCSAlzheimer's Disease Cooperative Study (ADCS). The ADCS was formed in 1991 as a  major initiative for Alzheimer’s disease (AD) clinical studies, addressing treatments for both cognitive and behavioral symptoms, particularly drugs that might not be developed by industry. UAB has participated in many ADCS-sponsored trials, and both Dr. Geldmacher and Dr. Marson have served on ADCS committees.